Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
25.2M
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
2.2M
-
Shares change
-
-62.1K
-
Total reported value, excl. options
-
$8.63M
-
Value change
-
-$470K
-
Number of buys
-
13
-
Number of sells
-
-12
-
Price
-
$3.92
Significant Holders of Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) as of Q4 2023
44 filings reported holding AXDX - Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share as of Q4 2023.
Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.2M shares
of 25.2M outstanding shares and own 8.73% of the company stock.
Largest 10 shareholders include GRIFFIN ASSET MANAGEMENT, INC. (1.22M shares), VANGUARD GROUP INC (307K shares), Cannell & Co. (115K shares), ORACLE INVESTMENT MANAGEMENT INC (112K shares), GEODE CAPITAL MANAGEMENT, LLC (87K shares), TCI Wealth Advisors, Inc. (58.7K shares), BlackRock Inc. (50.8K shares), NORTHERN TRUST CORP (46.1K shares), Belpointe Asset Management LLC (34.1K shares), and Cladis Investment Advisory, LLC (31.7K shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.